Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds
AssigneeAnteis S.A.
InventorFrank Dreher
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.
Claims77
A method for treating skin diseases and disorders associated with deregulation of the skin's antimicrobial peptide formation, processing, or both comprising administering an effective amount of one or more antimicrobial peptide sequestering compounds to a patient suffering therefrom.
A composition for treating skin diseases or disorders associated with deregulation of the skin's antimicrobial peptide formation, processing or both, wherein the composition is prepared from:
- a) a first phase comprising about 60.30% (by weight) water, about 0.1% disodium EDTA, about 0.25% (by weight) xantham gum, about 1.25% (by weight) ammonium acryloyldimethyltaurate/beheneth-25 methacrylate crosspolymer, and about 1.5% (by weight) hydroxypropyl starch phosphate;
- b) a second phase comprising about 14% (by weight) water, about 1.5% (by weight) caffeine;
- about 0.1% (by weight) dextran sodium sulfate, about 1% (by weight) zinc PCA, about 15% (by weight) glycerin), and about 1% (by weight) phenoxyethanol;
- c) a third phase comprising about 1% (by weight) hydroxylpropyl starch phosphate;
- and
- d) a fourth phase comprising about 3% caprylyl methicone,
- wherein the combined weight of all phases is 100% (by weight).
A composition for treating skin diseases or disorders associated with deregulation of the skin's antimicrobial peptide formation, processing or both, wherein the composition is prepared from:
- a) a first phase comprising about 60.30% (by weight) water, about 0.1% disodium EDTA, about 0.25% (by weight) xantham gum, about 1.25% (by weight) ammonium acryloyldimethyltaurate/beheneth-25 methacrylate crosspolymer, and about 1.5% (by weight) hydroxypropyl starch phosphate;
- b) a second phase comprising about 13.85% (by weight) water, about 1.5% (by weight) caffeine;
- about 0.25% (by weight) dextran sodium sulfate, about 1% (by weight) zinc PCA, about 15% (by weight) glycerin), and about 1% (by weight) phenoxyethanol;
- c) a third phase comprising about 1% (by weight) hydroxylpropyl starch phosphate;
- and
- d) a fourth phase comprising about 3% caprylyl methicone,
- wherein the combined weight of all phases is 100% (by weight).
A composition for treating skin diseases or disorders associated with deregulation of the skin's antimicrobial peptide formation, processing or both, wherein the composition is prepared from:
- a) a first phase comprising about 60.04% (by weight) water, about 0.1% disodium EDTA, about 0.25% (by weight) xantham gum, about 1% (by weight) hydroxypropyl starch phosphate, and about 1% (by weight) hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer and isohexadecane and polysorbate-60;
- b) a second phase comprising about 15% (by weight) water, about 1.5% (by weight) caffeine;
- about 0.5% (by weight) dextran sodium sulfate, about 1% (by weight) zinc PCA, about 0.2% (by weight) chlorphenesin, about 15% (by weight) glycerin), and about 0.5% (by weight) phenoxyethanol;
- c) a third phase comprising about 1.5% (by weight) hydroxylpropyl starch phosphate and about 0.41% (by weight) hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer and isohexadecane and polysorbate-60;
- and
- d) a fourth phase comprising about 2% caprylyl methicone,
- wherein the combined weight of all phases is 100% (by weight).
Dependencies are inferred from the claim text.